[Which is the role of the angiotensin II receptor blockers (ARBs) for the treatment of heart failure? Do we work based on evidence/recommendations or pharmaceutical industry pressure?].
Chronic heart failure (CHF) represents the first cause of hospitalization in persons older than 6o years in our environment. Beside its incidence and prevalence is increasing although new therapeutic treatments. We think the recommendations of the guidelines of clinical practise are an important instrument to make decisions, although sometimes it is used a numeric language little clear. We do not have either to forget that sometimes patients selected for the clinical trials aren t really representative. Finally to add that pharmaceutical industry spends a lot of money on investigating active basics, but as company itself is needs to obtain benefits. With all of this, in this article we try to study the role of angiotensin II receptor blockers (ARBs) occupy in the medic strategy for the planification of a patient s treatment with chronic heart failure.
de la Fuente Cid
R
R
Complexo Hospitalario Universitario, Santiago de Compostela, A Coruña, Spain. ramondfc@yahoo.es
Varela Román
A
A
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D004345:Drug Industry; D019317:Evidence-Based Medicine; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D017410:Practice Guidelines as Topic
D047228:Angiotensin II Type 1 Receptor Blockers